|

Irinotecan (CPT-11) Clinical Trials

4 actively recruiting trials

Pipeline

Phase 1: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Gruppo Oncologico del Nord-Ovest2
  • Zhejiang Doer Biologics Co., Ltd.1
  • Sun Yat-sen University1

Indications

  • Cancer4
  • Pancreatic Adenocarcinoma Advanced or Metastatic1
  • Gastrointestinal Cancer1
  • Pediatric Solid Tumor1
  • Colorectal Cancer1

Other4 trials

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Phase 1/2
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Phase 3
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Phase 3
UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.